Episode 297: ASCO GU 2024 - CONTACT-02 Part 2

Neeraj Agarwal, MD, FASCO, discusses the CONTACT-02 trial that analyzed the use of cabozantinib in combination with atezolizumab for the treatment of patients with metastatic castration-resistant prostate cancer.
Dr. Agarwal is a professor of medicine and a Presidential Endowed Chair of Cancer Research at the Huntsman Cancer Institute, University of Utah. He is also director of the institute’s Genitourinary Oncology Program, and the Center of Investigational Therapeutics.